{"protocolSection":{"identificationModule":{"nctId":"NCT01734811","orgStudyIdInfo":{"id":"MV130-SLG-002"},"secondaryIdInfos":[{"id":"2012-002450-24","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Inmunotek S.L.","class":"INDUSTRY"},"briefTitle":"Efficacy and Safety Evaluation in Recurrent Wheezing Attacks","officialTitle":"Randomized Double-blind Placebo-controlled, Parallel, Multi Centre Clinical Trial of Sublingual Bacterial Vaccine in Children With Recurrent Bronchospasm (Wheezing Attacks) for the Evaluation of Efficacy, Security and Clinical Impact.","acronym":"MV130"},"statusModule":{"statusVerifiedDate":"2020-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2012-10"},"primaryCompletionDateStruct":{"date":"2016-05","type":"ACTUAL"},"completionDateStruct":{"date":"2017-02","type":"ACTUAL"},"studyFirstSubmitDate":"2012-11-16","studyFirstSubmitQcDate":"2012-11-27","studyFirstPostDateStruct":{"date":"2012-11-28","type":"ESTIMATED"},"resultsFirstSubmitDate":"2020-05-28","resultsFirstSubmitQcDate":"2020-08-19","resultsFirstPostDateStruct":{"date":"2020-09-04","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-11-04","lastUpdatePostDateStruct":{"date":"2021-11-08","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Inmunotek S.L.","class":"INDUSTRY"},"collaborators":[{"name":"Unidad de Investigacion Medica en Epidemiologia Clinica","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The study will be conducted in two hospitals of the same geographic area. It will be included children \\<3-years-old with recurrent wheezing attacks, confirmed by the review of the medical records, in the previous 12 months or a shorter time for those younger than one year.","detailedDescription":"This randomized, double-blind, placebo-controlled, parallel-group study will included 120 children \\<3 years old with ≥3 episodes of wheezing during the previous year. They will receive active treatment or placebo for six months. The main outcome will be the number of wheezing attacks during one year. Other outcomes were duration and severity of wheezing attacks , symptom and medication scores, and use of health resources."},"conditionsModule":{"conditions":["Bronchospasm; Bronchiolitis","Bronchospasm; Bronchitis"],"keywords":["Vaccine","Bronchospasm"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"Randomized, double-blind, placebo-controlled, multi centre, parallel-group study","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":120,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"The subjects will receive daily placebo spray (2 puff of 100 µL) for 6 months, followed by other 6 months of observation","interventionNames":["Biological: Biological vaccine"]},{"label":"Biological vaccine","type":"EXPERIMENTAL","description":"The subjects will receive daily biological vaccines pray (2 puff of 100 µL) of for 6 months, followed by other 6 months of observation","interventionNames":["Biological: Biological vaccine"]}],"interventions":[{"type":"BIOLOGICAL","name":"Biological vaccine","description":"daily spray (2 puff of 100 µL) for six months","armGroupLabels":["Biological vaccine","Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Recurrent Bronchospasm (Wheezing Attacks)","description":"Assessment of reduction of bronchospasm (wheezing attacks) episodes at 12 months. The number of bronchospasm (wheezing attacks) episodes, in active and placebo group will be compared","timeFrame":"12 months"}],"secondaryOutcomes":[{"measure":"Duration (Days) of Wheezing Attacks (WA)","description":"Review of bronchospasm (wheezing attacks) duration per patient","timeFrame":"12 months"},{"measure":"Time Until Appearance of First WA","description":"time (days) until appearance of first wheezing attack (WA)","timeFrame":"12 months"},{"measure":"Number of Days With Wheezing Attacks During the Study","description":"Review of the number of days with wheezing attacks during the study","timeFrame":"12 months"},{"measure":"Number of Patients With Recurrent WA During the Study","description":"Review of number of patients with recurrent WA during the whole study","timeFrame":"12 months"},{"measure":"Symptom Score During Wheezing Attacks","description":"Total of Symptom score during wheezing attacks. The patients were reviewed at our clinics every three months. These scores were recorded daily in a diary card by the parents, who were duly instructed.\n\nScale use to evaluate symptom during wheezing attacks is called the Symptom scores (SS) scale. Minimum value is 0 (meant improvement) and maximum value (meant not improvement) is 3.\n\nThe rating was: 0=absent (no sign/symptom evident); 1=mild (sign/symptom clearly present, but easily tolerated); 2=moderate (definite awareness of sign/symptom that is bothersome but tolerable) and 3=severe (sign/symptom that is hard to tolerate; causes interference with activities of daily life and/or sleeping). Fever was scored as number of days with temperature over 37ºC.\n\nThe total symptom score was calculated as the sum of all individual scores during the wheezing attacks.","timeFrame":"12 months"},{"measure":"Medication Score During WA","description":"Review of medication consumption during wheezing attacks. The patients were reviewed at our clinics every three months. Medication scores were recorded daily in a diary card by the parents, who were duly instructed.\n\nMedication was rated from 0 (minimum value) and the maximum value correspond to the maximum medication consumed per 24h. Rating was according to Dreborg et al. with slight modifications: two points were given for one tablet of 4 mg of Montelukast, for one puff of 50 μg budesonide-equivalent or for one dose of oral prednisolone, and 3 for the inhalation of one puff of 200 μg budesonide-equivalent. In the case of antibiotics and antipyretic/-anti-inflammatory drugs, the number of daily doses of these drugs was recorded.\n\nThe total symptom score was calculated as the sum of all individual scores during the wheezing attacks.","timeFrame":"12 months"},{"measure":"Overall Symptom Score","description":"Review of symptoms during the whole study. The patients were reviewed at our clinics every three months. These scores were recorded daily in a diary card by the parents, who were duly instructed.\n\nScale use to evaluate symptom during wheezing attacks is called the Symptom scores (SS) scale. Minimum value is 0 (meant improvement) and maximum value (meant not improvement) is 3.\n\nThe rating was: 0=absent (no sign/symptom evident); 1=mild (sign/symptom clearly present, but easily tolerated); 2=moderate (definite awareness of sign/symptom that is bothersome but tolerable) and 3=severe (sign/symptom that is hard to tolerate; causes interference with activities of daily life and/or sleeping). Fever was scored as number of days with temperature over 37ºC.\n\nThe total symptom score was calculated as the sum of all individual scores during the whole study","timeFrame":"12 months"},{"measure":"Overall Medication Score","description":"Review of medication consumption during the whole study. The patients were reviewed at our clinics every three months. Medication scores were recorded daily in a diary card by the parents, who were duly instructed.\n\nMedication was rated from 0 (minimum value) and the maximum value correspond to the maximum medication consumed per 24h. Rating was according to Dreborg et al. with slight modifications: two points were given for one tablet of 4 mg of Montelukast, for one puff of 50 μg budesonide-equivalent or for one dose of oral prednisolone, and 3 for the inhalation of one puff of 200 μg budesonide-equivalent. In the case of antibiotics and antipyretic/-anti-inflammatory drugs, the number of daily doses of these drugs was recorded.\n\nThe total symptom score was calculated as the sum of all individual scores during the whole study.","timeFrame":"12 months"}],"otherOutcomes":[{"measure":"Use of Health and Social Resources During the Whole Period of the Study.","description":"The use of health and social resources during the study was also recorded: days of hospitalization in ward and/or intensive care unit, visits to the emergency units, unscheduled visits to the pediatrician and/or to the specialist, telephone calls to the pediatrician, complementary tests (chest radiogram, blood analysis, others), days of school absenteeism and caregiver-days when the children needed them. The data were obtained from the diary cards and confirmed through the review of medical records.\n\nMaximum value corresponds to the maximum days spent in health resources (specified above) and the minimum value corresponds to the minimum of days spent in health resources (specified above)","timeFrame":"12 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects whose parents /legal representative have given written informed consent.\n* Both gender\n* Subject up to 36 months of age.\n* Subjects with recurrent bronchospasms (wheezing attacks); 3 or more exacerbations in the last 12 months\n\nExclusion Criteria:\n\n* Subjects whose parents/legal representative have not given written informed consent.\n* Subjects out of aged range\n* Subjects with malignancies or chemotherapy treatment\n* Subjects included in another clinical trial in the last 12 months.\n* Subject in immunosuppressive or immunostimulatory treatment\n* Subjects who have received iv gamma globulin in the past 12 months.\n* Subjects diagnosed with candidiasis or fungal recurrent infections.\n* Subjects diagnosed with malabsorption syndrome\n* Subjects with clinical allergy to common aeroallergens in the geographical area.\n* Subjects with hepatitis virus infections, HIV and tuberculosis","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Months","maximumAge":"36 Months","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Miguel Casanovas, PhD; MD","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Hospital de Manises","city":"Manises","state":"Valencia","zip":"46940","country":"Spain","geoPoint":{"lat":39.49139,"lon":-0.46349}},{"facility":"Hospital Universitario y Politécnico La Fe","city":"Valencia","zip":"46026","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}}]},"referencesModule":{"references":[{"pmid":"21391984","type":"BACKGROUND","citation":"Alecsandru D, Valor L, Sanchez-Ramon S, Gil J, Carbone J, Navarro J, Rodriguez J, Rodriguez-Sainz C, Fernandez-Cruz E. Sublingual therapeutic immunization with a polyvalent bacterial preparation in patients with recurrent respiratory infections: immunomodulatory effect on antigen-specific memory CD4+ T cells and impact on clinical outcome. Clin Exp Immunol. 2011 Apr;164(1):100-7. doi: 10.1111/j.1365-2249.2011.04320.x."},{"pmid":"33705665","type":"DERIVED","citation":"Nieto A, Mazon A, Nieto M, Calderon R, Calaforra S, Selva B, Uixera S, Palao MJ, Brandi P, Conejero L, Saz-Leal P, Fernandez-Perez C, Sancho D, Subiza JL, Casanovas M. Bacterial Mucosal Immunotherapy with MV130 Prevents Recurrent Wheezing in Children: A Randomized, Double-Blind, Placebo-controlled Clinical Trial. Am J Respir Crit Care Med. 2021 Aug 15;204(4):462-472. doi: 10.1164/rccm.202003-0520OC."}]}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"October 2012 - May 2015 subjects enrollment. 120 children \\<3 years old with recurrent WA, defined as 3 or more episodes of WA during the previous year. . WA were confirmed by the review of the medical records. Aeroallergen sensitization at baseline was used as an exclusion criterion to avoid an eventual WA due to allergic asthma.","groups":[{"id":"FG000","title":"Placebo","description":"The subjects will receive daily placebo spray (2 puff of 100 µL) for 6 months, followed by other 6 months of observation\n\nBiological vaccine: daily spray (2 puff of 100 µL) for six months"},{"id":"FG001","title":"Biological Vaccine","description":"The subjects will receive daily biological vaccines pray (2 puff of 100 µL) of for 6 months, followed by other 6 months of observation\n\nBiological vaccine: daily spray (2 puff of 100 µL) for six months"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"58"},{"groupId":"FG001","numSubjects":"62"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"54"},{"groupId":"FG001","numSubjects":"59"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"3"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"\\<3 years old with recurrent WA, defined as 3 or more episodes of WA during the previous year.","groups":[{"id":"BG000","title":"Placebo","description":"The subjects will receive daily placebo spray (2 puff of 100 µL) for 6 months, followed by other 6 months of observation\n\nBiological vaccine: daily spray (2 puff of 100 µL) for six months"},{"id":"BG001","title":"Biological Vaccine","description":"The subjects will receive daily biological vaccines pray (2 puff of 100 µL) of for 6 months, followed by other 6 months of observation\n\nBiological vaccine: daily spray (2 puff of 100 µL) for six months"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"120"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"120"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Months","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"23","spread":"8"},{"groupId":"BG001","value":"23","spread":"7"},{"groupId":"BG002","value":"23","spread":"8"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"51"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"69"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Spain","categories":[{"measurements":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"120"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Recurrent Bronchospasm (Wheezing Attacks)","description":"Assessment of reduction of bronchospasm (wheezing attacks) episodes at 12 months. The number of bronchospasm (wheezing attacks) episodes, in active and placebo group will be compared","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"events","timeFrame":"12 months","groups":[{"id":"OG000","title":"Placebo","description":"The subjects will receive daily placebo spray (2 puff of 100 µL) for 6 months, followed by other 6 months of observation\n\nBiological vaccine: daily spray (2 puff of 100 µL) for six months"},{"id":"OG001","title":"Biological Vaccine","description":"The subjects will receive daily biological vaccines pray (2 puff of 100 µL) of for 6 months, followed by other 6 months of observation\n\nBiological vaccine: daily spray (2 puff of 100 µL) for six months"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"299"},{"groupId":"OG001","value":"176"}]}]}]},{"type":"SECONDARY","title":"Duration (Days) of Wheezing Attacks (WA)","description":"Review of bronchospasm (wheezing attacks) duration per patient","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"days","timeFrame":"12 months","groups":[{"id":"OG000","title":"Placebo","description":"The subjects will receive daily placebo spray (2 puff of 100 µL) for 6 months, followed by other 6 months of observation\n\nBiological vaccine: daily spray (2 puff of 100 µL) for six months"},{"id":"OG001","title":"Biological Vaccine","description":"The subjects will receive daily biological vaccines pray (2 puff of 100 µL) of for 6 months, followed by other 6 months of observation\n\nBiological vaccine: daily spray (2 puff of 100 µL) for six months"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","lowerLimit":"6.2","upperLimit":"11.0"},{"groupId":"OG001","value":"6.0","lowerLimit":"4.0","upperLimit":"9.5"}]}]}]},{"type":"SECONDARY","title":"Time Until Appearance of First WA","description":"time (days) until appearance of first wheezing attack (WA)","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"days","timeFrame":"12 months","groups":[{"id":"OG000","title":"Placebo","description":"The subjects will receive daily placebo spray (2 puff of 100 µL) for 6 months, followed by other 6 months of observation\n\nBiological vaccine: daily spray (2 puff of 100 µL) for six months"},{"id":"OG001","title":"Biological Vaccine","description":"The subjects will receive daily biological vaccines pray (2 puff of 100 µL) of for 6 months, followed by other 6 months of observation\n\nBiological vaccine: daily spray (2 puff of 100 µL) for six months"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","lowerLimit":"2.0","upperLimit":"28.8"},{"groupId":"OG001","value":"41.0","lowerLimit":"15.0","upperLimit":"94.5"}]}]}]},{"type":"SECONDARY","title":"Number of Days With Wheezing Attacks During the Study","description":"Review of the number of days with wheezing attacks during the study","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"days","timeFrame":"12 months","groups":[{"id":"OG000","title":"Placebo","description":"The subjects will receive daily placebo spray (2 puff of 100 µL) for 6 months, followed by other 6 months of observation\n\nBiological vaccine: daily spray (2 puff of 100 µL) for six months"},{"id":"OG001","title":"Biological Vaccine","description":"The subjects will receive daily biological vaccines pray (2 puff of 100 µL) of for 6 months, followed by other 6 months of observation\n\nBiological vaccine: daily spray (2 puff of 100 µL) for six months"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.0","lowerLimit":"17.0","upperLimit":"57.5"},{"groupId":"OG001","value":"19.2","lowerLimit":"8.5","upperLimit":"35.0"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Recurrent WA During the Study","description":"Review of number of patients with recurrent WA during the whole study","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"12 months","groups":[{"id":"OG000","title":"Placebo","description":"The subjects will receive daily placebo spray (2 puff of 100 µL) for 6 months, followed by other 6 months of observation\n\nBiological vaccine: daily spray (2 puff of 100 µL) for six months"},{"id":"OG001","title":"Biological Vaccine","description":"The subjects will receive daily biological vaccines pray (2 puff of 100 µL) of for 6 months, followed by other 6 months of observation\n\nBiological vaccine: daily spray (2 puff of 100 µL) for six months"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"36"}]}]}]},{"type":"SECONDARY","title":"Symptom Score During Wheezing Attacks","description":"Total of Symptom score during wheezing attacks. The patients were reviewed at our clinics every three months. These scores were recorded daily in a diary card by the parents, who were duly instructed.\n\nScale use to evaluate symptom during wheezing attacks is called the Symptom scores (SS) scale. Minimum value is 0 (meant improvement) and maximum value (meant not improvement) is 3.\n\nThe rating was: 0=absent (no sign/symptom evident); 1=mild (sign/symptom clearly present, but easily tolerated); 2=moderate (definite awareness of sign/symptom that is bothersome but tolerable) and 3=severe (sign/symptom that is hard to tolerate; causes interference with activities of daily life and/or sleeping). Fever was scored as number of days with temperature over 37ºC.\n\nThe total symptom score was calculated as the sum of all individual scores during the wheezing attacks.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"units on a scale","timeFrame":"12 months","groups":[{"id":"OG000","title":"Placebo","description":"The subjects will receive daily placebo spray (2 puff of 100 µL) for 6 months, followed by other 6 months of observation\n\nBiological vaccine: daily spray (2 puff of 100 µL) for six months"},{"id":"OG001","title":"Biological Vaccine","description":"The subjects will receive daily biological vaccines pray (2 puff of 100 µL) of for 6 months, followed by other 6 months of observation\n\nBiological vaccine: daily spray (2 puff of 100 µL) for six months"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"155.0","lowerLimit":"79.0","upperLimit":"244.5"},{"groupId":"OG001","value":"80.0","lowerLimit":"19.5","upperLimit":"154.5"}]}]}]},{"type":"SECONDARY","title":"Medication Score During WA","description":"Review of medication consumption during wheezing attacks. The patients were reviewed at our clinics every three months. Medication scores were recorded daily in a diary card by the parents, who were duly instructed.\n\nMedication was rated from 0 (minimum value) and the maximum value correspond to the maximum medication consumed per 24h. Rating was according to Dreborg et al. with slight modifications: two points were given for one tablet of 4 mg of Montelukast, for one puff of 50 μg budesonide-equivalent or for one dose of oral prednisolone, and 3 for the inhalation of one puff of 200 μg budesonide-equivalent. In the case of antibiotics and antipyretic/-anti-inflammatory drugs, the number of daily doses of these drugs was recorded.\n\nThe total symptom score was calculated as the sum of all individual scores during the wheezing attacks.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"units on a scale","timeFrame":"12 months","groups":[{"id":"OG000","title":"Placebo","description":"The subjects will receive daily placebo spray (2 puff of 100 µL) for 6 months, followed by other 6 months of observation\n\nBiological vaccine: daily spray (2 puff of 100 µL) for six months"},{"id":"OG001","title":"Biological Vaccine","description":"The subjects will receive daily biological vaccines pray (2 puff of 100 µL) of for 6 months, followed by other 6 months of observation\n\nBiological vaccine: daily spray (2 puff of 100 µL) for six months"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"424.0","lowerLimit":"185.0","upperLimit":"738.5"},{"groupId":"OG001","value":"164.0","lowerLimit":"43.5","upperLimit":"311.5"}]}]}]},{"type":"SECONDARY","title":"Overall Symptom Score","description":"Review of symptoms during the whole study. The patients were reviewed at our clinics every three months. These scores were recorded daily in a diary card by the parents, who were duly instructed.\n\nScale use to evaluate symptom during wheezing attacks is called the Symptom scores (SS) scale. Minimum value is 0 (meant improvement) and maximum value (meant not improvement) is 3.\n\nThe rating was: 0=absent (no sign/symptom evident); 1=mild (sign/symptom clearly present, but easily tolerated); 2=moderate (definite awareness of sign/symptom that is bothersome but tolerable) and 3=severe (sign/symptom that is hard to tolerate; causes interference with activities of daily life and/or sleeping). Fever was scored as number of days with temperature over 37ºC.\n\nThe total symptom score was calculated as the sum of all individual scores during the whole study","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"units on a scale","timeFrame":"12 months","groups":[{"id":"OG000","title":"Placebo","description":"The subjects will receive daily placebo spray (2 puff of 100 µL) for 6 months, followed by other 6 months of observation\n\nBiological vaccine: daily spray (2 puff of 100 µL) for six months"},{"id":"OG001","title":"Biological Vaccine","description":"The subjects will receive daily biological vaccines pray (2 puff of 100 µL) of for 6 months, followed by other 6 months of observation\n\nBiological vaccine: daily spray (2 puff of 100 µL) for six months"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"421.0","lowerLimit":"303.0","upperLimit":"673.0"},{"groupId":"OG001","value":"276.5","lowerLimit":"151.0","upperLimit":"426.0"}]}]}]},{"type":"SECONDARY","title":"Overall Medication Score","description":"Review of medication consumption during the whole study. The patients were reviewed at our clinics every three months. Medication scores were recorded daily in a diary card by the parents, who were duly instructed.\n\nMedication was rated from 0 (minimum value) and the maximum value correspond to the maximum medication consumed per 24h. Rating was according to Dreborg et al. with slight modifications: two points were given for one tablet of 4 mg of Montelukast, for one puff of 50 μg budesonide-equivalent or for one dose of oral prednisolone, and 3 for the inhalation of one puff of 200 μg budesonide-equivalent. In the case of antibiotics and antipyretic/-anti-inflammatory drugs, the number of daily doses of these drugs was recorded.\n\nThe total symptom score was calculated as the sum of all individual scores during the whole study.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"units on a scale","timeFrame":"12 months","groups":[{"id":"OG000","title":"Placebo","description":"The subjects will receive daily placebo spray (2 puff of 100 µL) for 6 months, followed by other 6 months of observation\n\nBiological vaccine: daily spray (2 puff of 100 µL) for six months"},{"id":"OG001","title":"Biological Vaccine","description":"The subjects will receive daily biological vaccines pray (2 puff of 100 µL) of for 6 months, followed by other 6 months of observation\n\nBiological vaccine: daily spray (2 puff of 100 µL) for six months"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1043.5","lowerLimit":"669.5","upperLimit":"1696.0"},{"groupId":"OG001","value":"618.5","lowerLimit":"318.3","upperLimit":"1035.5"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Use of Health and Social Resources During the Whole Period of the Study.","description":"The use of health and social resources during the study was also recorded: days of hospitalization in ward and/or intensive care unit, visits to the emergency units, unscheduled visits to the pediatrician and/or to the specialist, telephone calls to the pediatrician, complementary tests (chest radiogram, blood analysis, others), days of school absenteeism and caregiver-days when the children needed them. The data were obtained from the diary cards and confirmed through the review of medical records.\n\nMaximum value corresponds to the maximum days spent in health resources (specified above) and the minimum value corresponds to the minimum of days spent in health resources (specified above)","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"days","timeFrame":"12 months","groups":[{"id":"OG000","title":"Placebo","description":"The subjects will receive daily placebo spray (2 puff of 100 µL) for 6 months, followed by other 6 months of observation\n\nBiological vaccine: daily spray (2 puff of 100 µL) for six months"},{"id":"OG001","title":"Biological Vaccine","description":"The subjects will receive daily biological vaccines pray (2 puff of 100 µL) of for 6 months, followed by other 6 months of observation\n\nBiological vaccine: daily spray (2 puff of 100 µL) for six months"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"62"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.5","lowerLimit":"2","upperLimit":"52"},{"groupId":"OG001","value":"11.0","lowerLimit":"0","upperLimit":"44"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Up to 12 months.","description":"Adverse Events were registered throughout the trial. Grading was according to EAACI guidelines.","eventGroups":[{"id":"EG000","title":"Placebo","description":"The subjects will receive daily placebo spray (2 puff of 100 µL) for 6 months, followed by other 6 months of observation\n\nBiological vaccine: daily spray (2 puff of 100 µL) for six months","deathsNumAffected":0,"deathsNumAtRisk":58,"seriousNumAffected":1,"seriousNumAtRisk":58,"otherNumAffected":0,"otherNumAtRisk":58},{"id":"EG001","title":"Biological Vaccine","description":"The subjects will receive daily biological vaccines pray (2 puff of 100 µL) of for 6 months, followed by other 6 months of observation\n\nBiological vaccine: daily spray (2 puff of 100 µL) for six months","deathsNumAffected":0,"deathsNumAtRisk":62,"seriousNumAffected":0,"seriousNumAtRisk":62,"otherNumAffected":0,"otherNumAtRisk":62}],"seriousEvents":[{"term":"Epilectic seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAtRisk":62}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Medical Director","organization":"Inmunotek","email":"mcasanovas@inmunotek.com","phone":"916 510 010"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D001986","term":"Bronchial Spasm"},{"id":"D001988","term":"Bronchiolitis"},{"id":"D001991","term":"Bronchitis"}],"ancestors":[{"id":"D001982","term":"Bronchial Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D008173","term":"Lung Diseases, Obstructive"},{"id":"D008171","term":"Lung Diseases"}]}},"hasResults":true}